Pepgen inc. announces clinical hold in the u.s. on ind application to initiate a phase 1 study of pgn-edodm1 for myotonic dystrophy type 1 (dm1)

Boston, may 30, 2023 (globe newswire) -- pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the company received a clinical hold notice from the u.s. food and drug administration (fda) regarding their investigational new drug application (ind) to initiate a phase 1 study of pgn-edodm1 in patients with myotonic dystrophy type 1 (dm1). the fda indicated its intention to provide an official clinical hold letter to pepgen stating the reasons for the clinical hold within 30 days.
PEPG Ratings Summary
PEPG Quant Ranking